Prior to the isolation process, inhibiting the PD-1 pathway combined with anti-angiogenesis or other appropriate pathways, such as the CTLA-4 pathway already demonstrated good chances to trigger T cell responses with long term effects on tumor control in vivo. This evidence concerns the gene PDCD1 and neoplasm.